Major changes after 16-months after activation of hVEGF-A₁₆₅ expression.

<div><p>A. Liver: Encapsulated hepatocellular carcinoma was highly necrotic and focally calcified (Haematoxylin-eosin).</p> <p>B. Lung: Papillary adenocarcinoma. (Haematoxylin-eosin).</p> <p>C. Macroscopical changes in liver (box shows the area of the microscopical sections in F–H).</p> <p>D. Macroscopical changes in spleen, control spleen on the left (microscopical sections in I–K).</p> <p>E. Macroscopical changes in paratubarian area (microscopical sections in L–N).</p> <p>F. Cavernous hemangioma featuring focal hyalinization.</p> <p>G. The same tumor mass area with higher magnification (haematoxylin-eosin).</p> <p>H. Weak focal hVEGF-A₁₆₅ immunoreactivity was present in the same area (True Blue as a chromogen), arrows indicate positive cells.</p> <p>I–K. Fibrous scars formed by collagenous and elastic fibres surrounded by dilated cystic spaces, focally filled with blood and revealing inconsistently CD34 positive lining.</p> <p>I. Hematoxylin-eosin. (an arrow points to an area shown in K)</p> <p>J. CD34 immunostaining.</p> <p>K. The same area as in I with higher magnification (stained with Masson Trichrom).</p> <p>Asterix in I and J indicate the same area.</p> <p>L. Cystically dilated paratubarian spaces with signs of old haemorrhage and thrombus formation (marked with *), an open circle points to an area which was highly vascularized as shown in M. (CD31 immunostaining) and a box indicates an area which revealed focal hVEGF-A₁₆₅ immunopositivity shown in N. (hVEGF-A₁₆₅ immunostaining).</p> <p>Bar<b>:</b> F, I, J - 500 µm, G, H, K - 100 µm, A, B, M, N - 200 µm L - 1000 µm.</p>